Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Chief Commercial Officer | February 11, 2026 | February 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pacira BioSciences, Inc.
Report date February 11, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 100,934.268 |
Reported balance
After 2026-02-11 transaction · row 1
1 source rowRow 1 · 2026-02-11 · Grant · Acquired 51,714 · Balance 100,934.268 F1: Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACADIA PHARMACEUTICALS INC
Report date November 17, 2024 · Filed November 20, 2024
Section 16 reporting ended · disclosed 2024-11-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 62,521 |
Reported balance
After 2024-11-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-11-17 · Exercise / conversion · Acquired 9,913 · Balance 62,521 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2: Includes 431 shares of the Issuer's common stock acquired by the reporting person on November 15, 2024 pursuant to an employee stock purchase plan. |
| Common StockSEC Table I · non-derivative | Direct | 72,434 |
Reported balance
After 2024-11-17 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-11-17 · Exercise / conversion · Acquired 9,913 · Balance 72,434 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
| Common StockSEC Table I · non-derivative | Direct | 62,105 |
Reported balance
After 2024-11-19 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2024-11-19 · Sale · Disposed 10,329 · Balance 62,105 F3: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.7947 to $16.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,913 |
Reported balance
After 2024-11-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-11-17 · Exercise / conversion · Disposed 9,913 · Balance 9,913 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,913 |
Reported balance
After 2024-11-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-11-17 · Exercise / conversion · Disposed 9,913 · Balance 9,913 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F6: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2: Includes 431 shares of the Issuer's common stock acquired by the reporting person on November 15, 2024 pursuant to an employee stock purchase plan.
F3: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.7947 to $16.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.
F6: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2023 Filed Jan 11, 2023 01:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 532 | $17.13 | $9,113.32 |
DisclosureSEC source: 0001209191-23-002895 · doc4.xml · nonDerivative · entry 2 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,549 F3 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.13 to $17.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 06, 2023 Filed Jan 11, 2023 01:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 1,286 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002895 · doc4.xml · derivative · entry 4 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,287 Underlying: Common Stock · 1,286 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F6 · derivative.exercise_date: One-third of the shares subject to the restricted stock units vest on each of January 6, 2022, January 6, 2023 and January 6, 2024. F6 · derivative.expiration_date: One-third of the shares subject to the restricted stock units vest on each of January 6, 2022, January 6, 2023 and January 6, 2024. Read SEC document |
| January 06, 2023 Filed Jan 11, 2023 01:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 1,286 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-002895 · doc4.xml · nonDerivative · entry 1 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F2 · balance_after: Includes 358 shares of the Issuer's common stock acquired by the reporting person on May 16, 2022 pursuant to an employee stock purchase program. Read SEC document |
| May 02, 2022 Filed May 4, 2022 00:47 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 552 | $18.18 | $10,036.46 |
DisclosureSEC source: 0001209191-22-026937 · doc4.xml · nonDerivative · entry 2 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,437 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.18 to $18.4025, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 29, 2022 Filed May 4, 2022 00:47 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 1,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026937 · doc4.xml · derivative · entry 3 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,567 Underlying: Common Stock · 1,567 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F4 · derivative.exercise_date: 50% of the shares subject to the restricted stock units vest on each of April 29, 2022 and April 29, 2023. F4 · derivative.expiration_date: 50% of the shares subject to the restricted stock units vest on each of April 29, 2022 and April 29, 2023. Read SEC document |
| April 29, 2022 Filed May 4, 2022 00:47 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 1,567 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-026937 · doc4.xml · nonDerivative · entry 1 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 22:56 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 20,096 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023742 · doc4.xml · derivative · entry 2 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,096 Underlying: Common Stock · 20,096 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 22:56 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Options (Right to Buy) · Derivative | 68,966 | $0.00 Strike: $25.75 | $0.00 |
DisclosureSEC source: 0001209191-22-023742 · doc4.xml · derivative · entry 1 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,966 Underlying: Common Stock · 68,966 shares Expires 2032-04-05 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on April 5, 2023. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 22:45 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 1,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013284 · doc4.xml · derivative · entry 3 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,321 Underlying: Common Stock · 1,106 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23 2022. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23 2022. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 22:45 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 472 | $23.80 | $11,233.60 |
DisclosureSEC source: 0001209191-22-013284 · doc4.xml · nonDerivative · entry 2 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,422 F1 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 22:45 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 1,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013284 · doc4.xml · nonDerivative · entry 1 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 23:25 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 1,286 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002751 · doc4.xml · derivative · entry 3 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,573 Underlying: Common Stock · 1,286 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 23:25 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 538 | $23.05 | $12,400.90 |
DisclosureSEC source: 0001209191-22-002751 · doc4.xml · nonDerivative · entry 2 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,788 F3 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 23:25 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 1,286 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-002751 · doc4.xml · nonDerivative · entry 1 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 233 shares of the Issuer's common stock acquired by the reporting person on November 15, 2021 pursuant to an employee stock purchase program. Read SEC document |
| January 06, 2022 Filed Jan 11, 2023 01:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 1,286 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002895 · doc4.xml · derivative · entry 3 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,573 Underlying: Common Stock · 1,286 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F5 · derivative.exercise_date: This restricted stock units is being re-reported solely to correct vesting terms on the Form 4 filed on January 10, 2022, which erroneously indicated that the restricted stock units vest in four equal annual installments beginning January 6, 2021. The correct vesting is one-third of the shares subject to the restricted stock units vest on each of January 6, 2022, January 6, 2023 and January 6, 2024. Except as noted in this footnote, all other information as disclosed in the Reporting Person's original Form 4 was accurately reported. F5 · derivative.expiration_date: This restricted stock units is being re-reported solely to correct vesting terms on the Form 4 filed on January 10, 2022, which erroneously indicated that the restricted stock units vest in four equal annual installments beginning January 6, 2021. The correct vesting is one-third of the shares subject to the restricted stock units vest on each of January 6, 2022, January 6, 2023 and January 6, 2024. Except as noted in this footnote, all other information as disclosed in the Reporting Person's original Form 4 was accurately reported. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 23:35 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 39,651 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-065926 · doc4.xml · derivative · entry 2 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,651 Underlying: Common Stock · 39,651 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. F3 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 23:35 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 39,651 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-065926 · doc4.xml · derivative · entry 1 Teehan Brendan · CIK 0001891900 · EVP, COO, Head of Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,651 Underlying: Common Stock · 39,651 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F2 · derivative.exercise_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. F2 · derivative.expiration_date: The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.